10月30日 - ** Intensity Therapeutics的股价INTS.O盘前大涨128.6%至0.62美元
** 根据发表在《柳叶刀》杂志 eBioMedicine 上的一项研究，该公司的试验性抗癌药物 INT230-6 在晚期癌症患者中显示出令人鼓舞的效果
** INTS 称 INT230-6 在晚期癌症患者中显示出 75% 的疾病控制率 - eBioMedicine
** 研究人员称，将药物直接注入肿瘤；20%的患者未经治疗的肿瘤缩小了
** 公司的中位生存期为 11.9 个月；肉瘤患者的中位生存期增至 21.3 个月
** 截至上一交易日收盘，该公司股价年累计下跌约 85
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.